For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 4,175 | |||
| General and administrative | 5,778 | |||
| Operating loss | -9,953 | |||
| Financial expense, net | -533 | |||
| Gain on change in fair value of warrants liability (note 7) | -179 | |||
| Net loss | -10,307 | |||
| Basic EPS | -1.11 | |||
| Diluted EPS | -1.11 | |||
| Basic Average Shares | 9,268,976 | |||
| Diluted Average Shares | 9,268,976 | |||
BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
BRAINSTORM CELL THERAPEUTICS INC. (BCLI)